RecipientAmountDeal/Technology HighlightLead InvestorsDeal TypeCountry
Teva Pharmaceutical Industries$1,380 millionSale of Remaining Assets in Specialty Global Women’s Health Portfolio CVC Capital Partners Fund VI & Foundation Consumer HealthcareAcquisitionIsrael
NeoTract$1,100 millionNeoTract will greatly enhance Teleflex’s presence in the urological market as NeoTract’s UroLift® System is a novel solution used to address a significant medical issue and targets a total addressable market estimated at over $30 billion.Teleflex IncAcquisitionUnited States
Teva Pharmaceutical Industries $1,100 millionPARAGARD® (intrauterine copper contraceptive), a product within its global Women’s Health businessCooperSurgicalAcquisitionIsrael
Cook Pharmica$950 millionDevelopment and manufacturing facilityCatalentAcquisitionUnited States
Argon Medical Devices Inc$850 millionAgreement for medical-device company Shandong Weigao Group Medical Polymer CoAcquisitionUnited States
AstraZeneca $766 millionBuy the remaining rights to its anesthetic medicines in markets outside the US Aspen Global IncorporatedCommercialization Rights United Kingdom
Rigontec$603 millionPioneering therapeutic access to the retinoic acid-inducible gene I (RIG-I) pathwayMerck & Co.AcquisitionUnited Kingdom
Bicycle Therapeutics$424 millionDiscovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease.Bioverativ CollaborationUnited States
Arcus Bioscience$310 millionFor the potential development & commercialization of product candidates in Arcus’s portfolio in Japan and certain other territories in Asia (excluding China)Taiho PharmaLicense AgreementUnited States
Deciphera Pharmaceuticals, Nightstar Therapeutics and NuCana$303 millionFocusing on cancer and eye diseases UndisclosedIPO FundingUnited States
Gubra $300 millionFor the development of novel peptide compounds to treat obesityBoehringer IngelheimCollaboration & License AgreementDenmark
Therapure Biopharma Inc$290 millionTo acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market.3SBio Inc.AcquisitionCanada
Lightstone Ventures$250 millionTo focus on early-stage therapeutic opportunities across the life sciences sectorUndisclosedFund Raising United States
Quantum Pharma $196.4 millionUnlicensed to licensed UL2L capabilities Clinigen GroupAcquisitionUnited Kingdom
Presage Biosciences $183.9 million For Voruciclib, An Oral, Selective CDK InhibitorMEI PharmaLicense AgreementUnited States
BridgeBio Pharma$135 millionNovel treatments for genetic diseasesViking Global Investors & KKRInvestmentUnited States
Halozyme Therapeutics, Inc$105 millionENHANZE TechnologyBristol-Myers SquibbLicense AgreementUnited States
SpringWorks Therapeutics$103 millionTo developing innovative potential new treatments for underserved patient communitiesBain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer & LifeArcSeries A FinancingUnited States
Fred Hutchinson Cancer Research$94.5 millionNext-gen CAR-T for lymphoma/Expansion of CAR T Pipeline into CD20-Directed ImmunotherapiesMustang BioLicense AgreementUnited States
Gritstone Oncology $92.7 millionProceeds Will Support Further Development of Proprietary Tumor Antigen Identification Platform and Advancement of Pipeline of Personalized Cancer ImmunotherapiesLilly Asia Ventures, Google Ventures, Trinitas Capital (Beijing) and Alexandria Venture InvestmentsSeries B FinancingUnited States
Autolus $80 millionProceeds will be used to establish clinical proof of concept for three novel haematological cancer programsSyncona, Woodford & Arix BioscienceFinancingUnited Kingdom
MicroMass Communications$75.8 millionMicromass is a healthcare marketing agency specializing in digital, relationship marketing, and non-personal promotion. Our unique expertise in human health behavior allows us to create highly effective solutions for patients and health care providers.UDG Healthcare AcquisitionUnited States
Aptevo Therapeutics $74.5 millionTo Sell three of its marketed products (WinRho® SDF, HepaGam B®, and VARIZIG®)Saol TherapeuticsPurchage Agreement United States
Tempus $70 millionFocused on using genomic sequencing to help doctors customize cancer treatmentsRevolution Growth and New Enterprise AssociatesSeries C FinancingUnited States
LifeMine Therapeutics$55 million The company has hacked a code of biologic function hidden in biosynthetic genes that enables the rapid discovery of drugs for previously untargetable disease drivers.WuXi Healthcare VenturesSeries A FinancingUnited States
Replimune Group$55 millionTo generate clinical proof-of-concept data on its lead oncolytic immunotherapy.Foresite Capital Series B FinancingUnited States
Integra LifeSciences$48 millionNeurosurgery Assets - Camino ICP monitoring product line and associated productsNatus MedicalAcquisitionUnited States
Shanghai SinoMedCare Biotech$40 millionThe Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments.Fosun Pharma Stake AcquisitionChina
Immunocore$40 millionThe investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIVBill & Melinda Gates Foundation InvestmentUnited Kingdom
Arcturus Therapeutics$40 millionPlan to accelerate development of internal programs targeting rare diseasesAlcobraMergerUnited States
Immune Therapeutics$31 millionAgreement Illustrates Immune Therapeutics' Commitment to Providing an Effective and Affordable Non-Toxic Treatment for HIV/AIDS Patients Omaera PharmaceuticalsAgreementUnited States
Disarm Therapeutics$30 millionDisarm focuses on development treatments for neurological diseases by preventing axonal degenerationAtlas Venture, with co-investors Lightstone Ventures & AbbVie VenturesSeries A FinancingUnited States
Halozyme Therapeutics$30 millionENHANZE® drug-delivery technology Roche Collaboration & License AgreementUnited States
Janssen Pharmaceutica NV & Janssen Sciences Ireland UC$28 millionTwo Clinical-Stage Immunology AssetsProvention Bio License AgreementBelgium
Rodin Therapeutics$27 millionThe financing announced will fuel the ongoing development of innovative product candidates designed to treat neurological disorders, such as Alzheimer’s disease and Parkinson’s disease.Atlas Venture, GV (formerly Google Venture), Hatteras Venture Partners, Remeditex Ventures and Third Point VenturesFinancingUnited States
Integra Holdings$25 millionFunds will Contribute to Expansion and Development of Integra's Portfolio, Bringing Hebrew University's Life Science Innovations to Market. Temasek, Arie CapitalInvestmentIsrael
Analytics 4 Life $25 million To Advance its Artificial Intelligence-Backed Cardiac Imaging TechnologyUndisclosedSeries B FinancingCanada
Engage Therapeutics $23 millionTo Advance Phase 2b Development of Novel Epileptic Seizure Rescue TherapyTPG BiotechSeries A FinancingUnited States
Eligo Bioscience$20 millionTo take bacteria-killing CRISPR drug into clinicKhosla Ventures and Seventure PartnersSeries A FinancingFrance
Destiny Pharma$19.8 millionTo assess lead candidate XF-73 in the prevention of postsurgical staphylococcal infections in a phase 2b trial.UndisclosedIPO FundingUnited Kingdom
Novartis Suffern Partners LLC$18 millionResold 162-acre property in Suffern RS Old Mill Assets AcquisitionSwitzerland
XW Laboratories$17.5 millionUtilize funds to continue the development of its multiple programs that are entering clinical and IND-enabling studies.Elements Capital and WI Harper (WuXi, Johnson & Johnson)Series B FinancingChina
Thermalin$17.5 millionTo develop insulin therapies SanofiSeries A Financing & Collaboration United States
Technology Sciences Group$17 millionThe combined operations expand our presence in the global science and technology advisory marketScience Group plcAcquisitionUnited States
Opexa Therapeutics$15.7 millionAcer plans to file a NDA for its lead product, EDSIVO™, for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the first half of 2018.Acer Therapeutics IncMerger and FinancingUnited States
Bird & Cronin, Inc.$15.5 millionBird & Cronin will be operated following closing of the purchase as a wholly-owned subsidiary of Dynatronics.Dynatronics CorporationAcquisitionUnited States
Antidote Technologies$11 millionTo advance it's clinical trial patient matching platformMerck Global Health Innovation FundFund Raising United Kingdom
Camino Pharma$10.8 millionGrant for Development of Potential Drug for Cocaine and Nicotine AddictionNational Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH)FundingUnited States
Excision BioTherapeutics$10 millionTo start human testing of its CRISPR-enabled attack on latent HIV virusArtis VenturesSeed FundingUnited States
Landos Biopharma$10 millionTo take a LANCL2-targeted treatment for inflammatory bowel disease (IBD) into the clinic. Perceptive AdvisorsSeries A FinancingUnited States
AgeneBio$10 millionNovel GABAA discovery program to treat mild cognitive impairment due to Alzheimer's disease (MCI due to AD) and delay the onset of Alzheimer’s dementia. National Institutes of Health (NIH)FundingUnited States
DelMar Pharmaceuticals, Inc$10 millionRegistered Direct Offering Priced At-The-MarketUndisclosedSecurities Purchase AgreementCanada
Notable Labs$10 millionTo Advance Personalized Cancer TreatmentsBuilders VCSeries A FinancingUnited States
Destiny Pharma$8 millionSigned a binding framework agreement giving CMS the rights to develop and commercialize Destiny's MRSA treatment, XF-73, in AsiaChina Medical Systems InvestmentUnited Kingdom
PSR Group$6.69 millionOrphan drug development Ergomed AcquisitionUnited Kingdom
Cellect Biotechnology$4.3 millionStem cells selection technologyUndisclosedSecurities Purchase AgreementIsrael
BioSensics$2.5 millionTo Develop a Novel Telecare Solution for Huntington’s Disease National Institutes of Health (NIH)FundingUnited States
Imperial College London$1 millionTo Develop Enhanced Surgical Techniques In Sports MedicineSmith & NephewPartnershipUnited Kingdom
Soligenix$0.7 millionThermostabilization of an Ebola Vaccine Candidate UH Manoa and Hawaii Biotech, Inc.Collaboration/Funding United States
The University Of Queensland Animal Genetics Laboratory UndisclosedAnimal genomics business Neogen Corporation AcquisitionAustralia
VIBUndisclosedUnique Portfolio Of Next-Generation Immuno-Oncology AssetsOncurious AcquisitionBelgium
Metabolomic Discoveries GmbHUndisclosedAcquisition Advances Metabolon’s European Presence and World-Wide Leadership in Metabolomics Metabolon AcquisitionGermany
Agility ClinicalUndisclosedFocused specifically on clinical development of rare disease and orphan therapiesPrecision For MedicineAcquisitionUnited States
TrevigenUndisclosedAs more drug testing is being conducted on physiologically more appropriate cell modelsBio-TechneAcquisitionUnited States
Vertera SpineUndisclosed Implants for spinal fusion using patented porous polyetheretherketone (PEEK) technologyNuVasive AcquisitionUnited States
Qualyst Transporter SolutionUndisclosedIn vitro hepatic models and services BioIVT AcquisitionUnited States
Nexeon Medsystems Belgium, SPRLUndisclosedDeveloping neurostimulation productsNexeon MedSystemsAcquisitionBelgium
University of New MexicoUndisclosedTechnology To Treat Leukemia A therapeutic monoclonal antibody for B-cell precursor acute lymphoblastic leukemia Pascal BiosciencesLicense Option AgreementUnited States
OPC Holding CompanyUndisclosedClinical CROTPG Capital AsiaAcquisitionTaiwan
Altum Pharmaceuticals UndisclosedBiPhasix™ Transdermal Drug Delivery technology Pivot PharmaceuticalsAgreementCanada
AlphaeonUndisclosedShoutMD social media platform in its entirety, including all technology and intellectual property rightsStrathspey Crown Holdings AgreementUnited States
Rocket PharmaUndisclosedCompany to Leverage Lentiviral and AAV Gene Therapy Platforms to Target Rare Genetic Diseases Inotek Pharmaceuticals CorporationMergerUnited States
Nuvelution PharmaUndisclosedTo Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United StatesTeva PharmaceuticalPartnershipUnited States
VenitiUndisclosedVICI VENOUS STENT®Boston Scientific Limited Global Distribution AgreementUnited States
Phosplatin TherapeuticsUndisclosedTo evaluate PT-112, a novel small molecule inducer of apoptosis with evidence of downstream immunogenic cell death (ICD) properties, currently in Phase I development, in combination with avelumab*, a human anti-PD-L1 IgG1 monoclonal antibody.Pfizer and Merck KGaACollaborationUnited States
GSK Consumer Healthcare UndisclosedThis acquisition is an important component of our strategic plan and expands our services by adding additional solid dose capability in the United StatesAvara Pharmaceutical Services AcquisitionUnited States
Bristol-Myers SquibbUndisclosedClinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors. ABBV-399 to explore the tolerability and potential efficacy of the combination in subjects with advanced c-Met overexpressing NSCLC AbbVieCollaborationUnited States
Inceptua MedicinesUndisclosedHAEi Global Access Program for RUCONESTPharming Group N.V & HAEi International Limited Global Distribution AgreementLuxembourg
Valensa International UndisclosedTo Introduce Algae-Sourced Beta-Glucan Ingredients for Immune HealthKemin Limited Global Distribution AgreementUnited States
Eli LillyUndisclosedTo create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death.Geisinger & Boehringer Ingelheim CollaborationUnited States
Bristol-Myers SquibbUndisclosedClinical Collaboration Evaluating IPI-549 in Combination with Opdivo Infinity PharmaceuticalsCollaborationUnited States
Boehringer Ingelheim Undisclosed Develop New Technology for Monitoring Anti-tumor Activity of the Immune SystemImaginAb IncCollaborationGermany
Analytical Biochemical LaboratoryUndisclosedTo Sponsors with botanical & drug discovaryArdenaAcquisitionNetherlands
Simcere UndisclosedTo Co-Develop And Commercialize Biosimilars In ChinaAmgen CollaborationChina
BioLineRx UndisclosedInitiation of Phase 1b/2 Trial for BL-8040 in AML Under Immunotherapy GenentechCollaborationIsrael
Foresee PharmaceuticalsUndisclosedFor the commercialisation in Turkey and certain Middle East countries of Foresee's FP-001 program, LMIS (Leuprolide Mesylate Injectable Suspension) ready-to-use subcutaneous depot formulations.TRPharmLimited Global Distribution AgreementTaiwan
UC BerkeleyUndisclosedTo tackle 'undruggable' disease targetsNovartis CollaborationUnited States
Shiel Medical Laboratory (Fresenius Medical Care)UndisclosedShiel Medical Laboratory businessQuest DiagnosticsAcquisitionUnited States
Berkeley LightsUndisclosedStrategic project to discover antibodies and ramp up the development of cell lines.Bayer AGCollaborationUnited States
Noile-Immune Biotech UndisclosedTo Advance Next Generation CAR-T Cell Therapy Effective for Solid TumorsTakeda CollaborationJapan
Breckenridge Pharmaceutical, IncUndisclosedTo Commercialize The Generic Version Of A Leading Corticosteroid Product Upon FDA ApprovalImpoPharmaLicense & Commercialization Agreement United States
Alexza Pharmaceuticals, IncUndisclosedInhaled Therapy ADASUVE Approved To Treat Agitation Associated With Schizophrenia And Bipolar I DisorderGalen US IncUS Commercialization RightsUnited States
Invicro LLCUndisclosedThrough molecular digital imaging technology, acquisition offers new value for drug discovery and development focused on the fields of immuno-oncology and neurodegenerative disease.Konica Minolta, Inc.AcquisitionUnited States
DePuy Synthes (Johnson & Johnson )UndisclosedProdisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systemsCentinel SpineAssets AcquisitionUnited States
GE Corporation UndisclosedExpands Life Sciences Industry Cook GroupAgreementUnited Kingdom
Triple RedUndisclosedEfforts to offer a broader range of products and solutions to the research community.Edstrom IndustriesAcquisitionUnited Kingdom
MedVantxUndisclosedMedStart Connect Sample Kiosk ProgramQPharma, Inc. Assets AcquisitionUnited States
Imanova UndisclosedCombined business delivers world-leading imaging capabilities to drive improved decision-making from early drug discovery to late-phase clinical developmentInvicroAcquisitionUnited Kingdom
Vantage Medical SuppliesUndisclosedTo acquire Vantage Medical Supplies, a major distributor of medical and surgical equipment based in Holtsville, New York.Dealmed Medical SuppliesAcquisitionUnited States
Medical Imaging SystemsUndisclosedIt will also provide additional leadership to enhance the delivery of imaging equipment to our growing installed base in and around eastern PennsylvaniaAlpha Imaging AcquisitionUnited States
MERLIN Diagnostika GmbHUndisclosedTo Add Selected Antibiotic Resistance And Susceptibility Testing To Its MALDI Biotyper Microbial Identification PlatformBruker CorporationAcquisitionGermany